Antipsychotic Agents
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment
Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment
Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar
Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials